Literature DB >> 18314323

Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome.

Viktor Hanak1, Jay H Ryu, Erika de Carvalho, Andrew H Limper, Thomas E Hartman, Paul A Decker, Jeffrey L Myers.   

Abstract

RATIONALE: The prognostic significance of fibroblast foci in surgical lung biopsies from patients with idiopathic pulmonary fibrosis (IPF) is unclear.
OBJECTIVES: We assessed the relationship between profusion of fibroblast foci and survival in 43 patients with IPF seen at a tertiary referral medical center from 1996 to 2002.
METHODS: Fibroblast foci in surgical lung biopsies were counted using a systematic morphometric point-counting technique. Patients with either clinical or pathologic evidence of accelerated disease were excluded from analysis. The association of fibroblast counts with survival was assessed using proportional hazards regression.
RESULTS: The mean age (+/-SD) of the study population was 64+/-9 years; 26 (60%) patients were male. The mean (%+/-SD) profusion of fibroblastic foci was 0.6+/-0.7, expressed as a percentage of total points counted. Fibroblast foci counts did not differ markedly between upper, middle, and lower lobes. Median survival from the time of biopsy was 2.4 years; there were 25 (58%) deaths in the follow up period. There was no significant relationship between profusion of fibroblast foci and survival in the overall group (p=0.250).
CONCLUSIONS: Higher prevalence of fibroblast foci assessed using a simple point-counting technique applied to surgical lung biopsies is not associated with survival in patients with clinically stable IPF.

Entities:  

Mesh:

Year:  2008        PMID: 18314323     DOI: 10.1016/j.rmed.2008.01.012

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

Review 1.  Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer; Mark L Lupher
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Local origin of mesenchymal cells in a murine orthotopic lung transplantation model of bronchiolitis obliterans.

Authors:  Takeshi Mimura; Natalie Walker; Yoshiro Aoki; Casey M Manning; Benjamin J Murdock; Jeffery L Myers; Amir Lagstein; John J Osterholzer; Vibha N Lama
Journal:  Am J Pathol       Date:  2015-04-04       Impact factor: 4.307

4.  Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis.

Authors:  Seung-Ick Cha; Christine S Chang; Eun Kyung Kim; Jae W Lee; Michael A Matthay; Jeffrey A Golden; Brett M Elicker; Kirk Jones; Harold R Collard; Paul J Wolters
Journal:  Histopathology       Date:  2012-03-06       Impact factor: 5.087

5.  Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival.

Authors:  Jonathan Keow; Matthew J Cecchini; Nathashi Jayawardena; Maurizio Zompatori; Mariamma G Joseph; Marco Mura
Journal:  Respir Res       Date:  2022-06-07

Review 6.  The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.

Authors:  Fernando J Martinez; Alison Chisholm; Harold R Collard; Kevin R Flaherty; Jeffrey Myers; Ganesh Raghu; Simon L F Walsh; Eric S White; Luca Richeldi
Journal:  Lancet Respir Med       Date:  2016-12-06       Impact factor: 30.700

7.  Medical Research Council dyspnea scale does not relate to fibroblast foci profusion in IPF.

Authors:  Christina Triantafillidou; Effrosyni D Manali; Christina Magkou; Christina Sotiropoulou; Likurgos F Kolilekas; Konstantinos Kagouridis; Dimitra Rontogianni; Spyros A Papiris
Journal:  Diagn Pathol       Date:  2011-04-05       Impact factor: 2.644

8.  Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis.

Authors:  Mark G Jones; Aurélie Fabre; Philipp Schneider; Francesco Cinetto; Giacomo Sgalla; Mark Mavrogordato; Sanjay Jogai; Aiman Alzetani; Ben G Marshall; Katherine M A O'Reilly; Jane A Warner; Peter M Lackie; Donna E Davies; David M Hansell; Andrew G Nicholson; Ian Sinclair; Kevin K Brown; Luca Richeldi
Journal:  JCI Insight       Date:  2016-04-21

Review 9.  The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis.

Authors:  Riitta Kaarteenaho
Journal:  Respir Res       Date:  2013-04-15

Review 10.  Lymphangiogenesis and Lesion Heterogeneity in Interstitial Lung Diseases.

Authors:  Masahiro Yamashita
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2016-01-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.